ANTI-ADHESION DEVICE PREMARKET REQUIREMENTS RECONSIDERED BY FDA AFTER PANEL VOTES AGAINST APPROVAL OF GENZYME'S SEPRACOAT; AGENCY MAY HOLD PUBLIC FORUM